Sign up to our newsletter Subscribe
Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.